BlackBarn Capital Partners LP In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), BlackBarn Capital Partners LP reported 20 stock positions worth $301.8 million . Its top holding was Roivant Sciences (ROIV) at 17.3% of the portfolio, followed by Amneal Pharmaceuticals (AMRX, 9.2% ) and Axcelis Technologies (ACLS, 8.3% ). Compared with Q1 2025, it opened 4 new positions, sold out of 2, added to 5 and reduced 5. The biggest buy was a new position in Nextera Energy (NEE) and the biggest sale an exit from Unitedhealth (UNH).
Location NEW YORK, NY
CIK 0002010204
Portfolio Value $301.8M (Q2 2025) Holdings 20 stocks · $301.8M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q1 2025 ROIV Roivant Sciences Ltd. 17.27% 4,625,000 $52.1M Reduce -2.6% AMRX Amneal Pharmaceuticals Inc. 9.24% 3,446,570 $27.9M Add +19.6% ACLS Axcelis Technologies Inc. 8.31% 360,000 $25.1M Reduce -25.1% DHC Diversified Healthcare Trust 7.41% 6,250,000 $22.4M No change MOH Molina Healthcare Inc. 7.40% 75,000 $22.3M Reduce -21.5% TEVA Teva Pharmaceutical-SP ADR 5.83% 1,050,000 $17.6M No change NEE Nextera Energy Inc. 5.75% 250,000 $17.4M New PRVA Privia Health Group Inc. 5.72% 750,000 $17.3M No change NXT Nextpower Inc. filed as NEXTRACKER INC 5.59% 310,000 $16.9M Reduce -13.9% INTC Intel Corp. 4.08% 550,000 $12.3M New CCOI Cogent Communications Holdin 3.83% 240,000 $11.6M Add +26.3% EGBN Eagle Bancorp Inc. 3.44% 532,181 $10.4M Add +40.0% VKTX Viking Therapeutics Inc. 3.07% 350,000 $9.3M New BRBS Blue Ridge Bankshares Inc. 2.82% 2,368,234 $8.5M Reduce -45.1% ABUS Arbutus Biopharma Corp. 2.67% 2,603,521 $8.0M Add +11.2% BVFL BV Financial Inc. filed as BV FINL INC 2.42% 480,000 $7.3M No change FBLA FB Bancorp Inc. 2.33% 624,700 $7.0M Add +3.3% HBNC Horizon Bancorp Inc. 1.53% 300,000 $4.6M No change PRO Pros Holdings Inc. 1.18% 227,387 $3.6M New MODVQ Modivcare Inc. 0.10% 100,577 $314K No change
Options reported separately and not counted above: SPY puts ($772.3M), TSLA puts ($603.6M), ARKK puts ($70.3M).
Portfolio Sells Q1 2025 → Q2 2025 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2025 % Of Portfolio Change To Portfolio ▲ UNH Unitedhealth Group Inc. Sold out 0.00% −11.81 MOH Molina Healthcare Inc. Reduce -21.5% 7.40% −3.34 RH RH Sold out 0.00% −2.40 BRBS Blue Ridge Bankshares Inc. Reduce -45.1% 2.82% −1.99 ACLS Axcelis Technologies Inc. Reduce -25.1% 8.31% +0.16 NXT Nextpower Inc. Reduce -13.9% 5.59% +0.40 ROIV Roivant Sciences Ltd. Reduce -2.6% 17.27% +0.90
Portfolio Buys Q1 2025 → Q2 2025 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2025 % Of Portfolio Change To Portfolio ▼ NEE Nextera Energy Inc. New 5.75% +5.75 INTC Intel Corp. New 4.08% +4.08 VKTX Viking Therapeutics Inc. New 3.07% +3.07 PRO Pros Holdings Inc. New 1.18% +1.18 AMRX Amneal Pharmaceuticals Inc. Add +19.6% 9.24% +0.99 EGBN Eagle Bancorp Inc. Add +40.0% 3.44% +0.71 FBLA FB Bancorp Inc. Add +3.3% 2.33% +0.00 ABUS Arbutus Biopharma Corp. Add +11.2% 2.67% −0.13 CCOI Cogent Communications Holdin Add +26.3% 3.83% −0.14
Options Activity Q1 2025 → Q2 2025 Security Type Change vs Q1 2025 Underlying Shares Value ▼ TSLA Tesla Inc. put Add +280.0% 1,900,000 $603.6M HYG Ishr Ibx Usd Hiyld CB ETF-Ui put Sold out 5,500,000 $433.9Mbefore exit ARKK ARK Innovation ETF put New 1,000,000 $70.3M WBA Walgreens Boots Alliance Inc. put Sold out 1,500,000 $16.8Mbefore exit
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 17 $402.2M ROIV, PRVA, DHC, NEE, NIQ Q1 2026 14 $332.4M ROIV, VECO, PRVA, DHC, NEE Q4 2025 11 $278.9M ROIV, DHC, PRVA, NIQ, NEE Q3 2025 15 $306.4M ROIV, PRVA, DHC, NXT, AMRX Q2 2025 20 $301.8M ROIV, AMRX, ACLS, DHC, MOH Q1 2025 18 $292.8M ROIV, UNH, MOH, AMRX, ACLS Q4 2024 15 $254.1M ROIV, UNH, MOH, TEVA, AMRX Q3 2024 18 $230.1M ROIV, MOH, AMRX, DHC, T Q2 2024 17 $194.0M ROIV, UNH, MOH, AMRX, BRBS Q1 2024 21 $173.0M ROIV, MOH, UNH, CHRD, CF